New Pill-and-Shot combo aims to wipe out HER2+ breast cancer before surgery
NCT ID NCT07095023
First seen May 02, 2026 · Last updated Jun 17, 2026 · Updated 6 times
Summary
This study tests whether taking an oral chemotherapy (paclitaxel) along with a fixed-dose injection of two targeted drugs (pertuzumab and trastuzumab) can eliminate all signs of HER2-positive breast cancer before surgery. About 112 adults with early-stage HER2+ breast cancer will receive this combination before their operation. The main goal is to see if the cancer completely disappears in the breast and lymph nodes at the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital of Shantou University Medical College
NOT_YET_RECRUITINGShantou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Guangdong Women and children Hospital
NOT_YET_RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Guangxi Provincial Cancer Hospital
NOT_YET_RECRUITINGNanning, Guangxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hainan Central Hospital
NOT_YET_RECRUITINGHaikou, Hainan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking University Cancer Hospital
NOT_YET_RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking University Shenzhen Hospita
NOT_YET_RECRUITINGShenzhen, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sun Yat-sen Memorial Hospital
RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Affiliated Hospital of Guizhou Medical University
NOT_YET_RECRUITINGGuiyang, Guizhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
the First Affiliated Hospital of Wenzhou Medical University
NOT_YET_RECRUITINGWenzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.